Johnson & Johnson (JNJ) Shares Sold by RKL Wealth Management LLC

RKL Wealth Management LLC reduced its stake in Johnson & Johnson (NYSE:JNJ) by 1.9% during the fourth quarter, according to its most recent filing with the SEC. The fund owned 50,376 shares of the company’s stock after selling 991 shares during the quarter. Johnson & Johnson accounts for approximately 1.7% of RKL Wealth Management LLC’s portfolio, making the stock its 15th largest holding. RKL Wealth Management LLC’s holdings in Johnson & Johnson were worth $7,033,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of JNJ. Stifel Financial Corp boosted its holdings in shares of Johnson & Johnson by 6,715.9% in the 3rd quarter. Stifel Financial Corp now owns 2,572,663 shares of the company’s stock worth $334,777,000 after buying an additional 2,534,918 shares during the last quarter. Cornerstone Investment Partners LLC lifted its holdings in Johnson & Johnson by 91.4% during the fourth quarter. Cornerstone Investment Partners LLC now owns 1,512,352 shares of the company’s stock valued at $211,306,000 after purchasing an additional 722,113 shares during the last quarter. Schwab Charles Investment Management Inc. lifted its holdings in Johnson & Johnson by 4.6% during the fourth quarter. Schwab Charles Investment Management Inc. now owns 12,576,360 shares of the company’s stock valued at $1,757,159,000 after purchasing an additional 551,632 shares during the last quarter. Atlantic Trust Group LLC lifted its holdings in Johnson & Johnson by 23.4% during the third quarter. Atlantic Trust Group LLC now owns 2,060,040 shares of the company’s stock valued at $267,827,000 after purchasing an additional 391,068 shares during the last quarter. Finally, Fisher Asset Management LLC lifted its holdings in Johnson & Johnson by 2.8% during the fourth quarter. Fisher Asset Management LLC now owns 12,127,379 shares of the company’s stock valued at $1,694,437,000 after purchasing an additional 329,705 shares during the last quarter. 67.40% of the stock is currently owned by institutional investors.

Shares of JNJ opened at $123.85 on Friday. Johnson & Johnson has a twelve month low of $125.00 and a twelve month high of $125.73. The stock has a market cap of $336.30 billion, a PE ratio of 16.97, a P/E/G ratio of 1.92 and a beta of 0.74. The company has a current ratio of 1.58, a quick ratio of 1.25 and a debt-to-equity ratio of 0.47.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, April 17th. The company reported $2.06 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.00 by $0.06. Johnson & Johnson had a return on equity of 30.65% and a net margin of 1.58%. The firm had revenue of $20.01 billion for the quarter, compared to analysts’ expectations of $19.50 billion. During the same period in the prior year, the business posted $1.83 earnings per share. The company’s revenue was up 12.6% on a year-over-year basis. sell-side analysts predict that Johnson & Johnson will post 8.13 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 12th. Stockholders of record on Tuesday, May 29th will be given a dividend of $0.90 per share. The ex-dividend date of this dividend is Friday, May 25th. This is a boost from Johnson & Johnson’s previous quarterly dividend of $0.84. This represents a $3.60 annualized dividend and a dividend yield of 2.91%. Johnson & Johnson’s dividend payout ratio is currently 46.03%.

Several equities research analysts have commented on JNJ shares. Zacks Investment Research downgraded shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Monday, April 9th. Jefferies Group set a $153.00 price objective on shares of Johnson & Johnson and gave the company a “buy” rating in a report on Friday, April 13th. Vetr downgraded shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating and set a $124.55 price objective on the stock. in a report on Monday, March 26th. Credit Suisse Group set a $154.00 price objective on shares of Johnson & Johnson and gave the company a “hold” rating in a report on Monday, January 22nd. Finally, Goldman Sachs set a $134.00 price objective on shares of Johnson & Johnson and gave the company a “sell” rating in a report on Tuesday, April 17th. Five research analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have issued a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $142.23.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply